← Back to patent-cliff list
Tobramycin/Edetate Calcium sodium
Tier C — Watch / tradeTobramycin/Edetate Calcium sodium
Respirion Pharmaceuticals Pty Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：30S subunit
Indications (approved)：Respiratory tract infection, Pseudomonas infection, Cystic fibrosis
Regional status
US
Phase II
2024-04-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tobramycin/Edetate Calcium sodium?
Approved indications include: Respiratory tract infection, Pseudomonas infection, Cystic fibrosis.
When does the Tobramycin/Edetate Calcium sodium patent expire?
No public expiry year is available for Tobramycin/Edetate Calcium sodium yet; this page updates once verified.
How do I get a quote for Tobramycin/Edetate Calcium sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01